ADC Therapeutics, a Swiss-based late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of antibody drug conjugates, announced the pricing of its upsized follow-on public offering of shares in the United States, thus raising gross proceeds of approx. USD 204 million. In addition, certain existing shareholders had granted the underwriters an option to purchase additional shares for an aggregate amount of up to USD 30.6 million.
Morgan Stanley, BofA Securities and Cowen were acting as joint book-running managers for the offering. RBC Capital Markets was acting as co-manager for the offering.